Integra LifeSciences reaffirms full-year earnings guidance and projects third-quarter revenue between $410M and $425M.
Integra LifeSciences maintained its adjusted earnings per share forecast for Q2 2026 at $2.40 to $2.50. The company also guided third-quarter revenue to a range of $410M to $425M, reflecting steady operational performance.
The guidance aligns with prior expectations and follows a second quarter where Integra delivered on key commitments. Management highlighted progress across business priorities, though no specific market reaction was noted in the update.
CEO Stuart Essig expressed encouragement over Q2 results, citing achieved milestones and advanced strategic initiatives.